Citations 1
Race and Outcomes to [177Lu]Lu-PSMA-617 in Advanced Prostate Cancer
Rami, Avina , Zhong, Caiwei , Muniz, Miguel, Khorasanchi, Adam , Fein, Daniel , Stoltenberg, Hailey, Gopalakrishan, Dharmesh, Yang, Yuanquan , Ng, Thomas S.C. , Gafita, Andrei , Jacene, Heather A. , Ravi, Praful , Muniz, Miguel , Khorasanchi, Adam , Fein, Daniel , Ng, Thomas S C , Childs, Daniel S , Xie, Wanling , Gallagher, John F. , Mohammadi, Sedra, Voter, Andrew F. , Childs, Daniel S.
Cancers | June 12, 2025 | Volume: 17 | Issue: 12 | Pages: 1960
Black patients with metastatic prostate cancer have higher mortality rates compared to non-Hispanic White patients. There are no data on outcomes with [177Lu]Lu-PSMA-617 (LuPSMA) across racial groups. We evaluated the association between race and outcomes with LuPSMA in a multi-institutional cohort of consecutive patients with mCRPC treated with LuPSMA. The primary outcomes were PSA-50 rate, PSA-progression-free survival (PSA-PFS), and overall survival (OS). Statistical models were adjusted for age, number of prior therapies, sites of metastases, and baseline PSA. A total of 654 patients were included; 593 (91%) were White, 45 (7%) were Black and 16 (2%) were another non-Black minority (NBM). There were no statistically significant differences in PSA-50 rates, PSA-PFS and OS between the groups. Black and White patients treated with LuPSMA had similar clinical outcomes; efforts are needed to ensure Black and NBM patients have equal access to life prolonging therapies to narrow disparities in outcomes.